The company manufactures and processes aluminum foils and flexible packaging materials primarily for the pharmaceutical, food, and FMCG industries, operating from a single integrated facility in Rajasthan.
While the company claims a moat based on its integrated manufacturing and long-standing pharma relationships, the financial metrics contradict this. Average ROCE of 8.3% and net margins below 5% suggest a commodity-like business with no durable pricing power or cost advantage.
Capital allocation is poor, characterized by low returns on equity and a recent net loss. The company maintains high cash balances that are not effectively deployed to generate incremental returns, and it has a history of failed or withdrawn preferential warrant issuances.
The business succumbed to a toxic combination of operational inefficiency and governance decay. The unresolved 69 crore INR bank fraud and subsequent Income Tax search and seizure signaled a culture of internal control failure that eventually led to a total breakdown in creditor trust. As LME price volatility squeezed the already razor-thin 4.7% margins, the company's inability to convert sales to cash—evidenced by its negative cash conversion—resulted in a liquidity crunch. Without a durable moat to pass on costs, the firm was unable to service its debt or reinvest, leading to a slow-motion liquidation of shareholder value.
RichFakir rates PG Foils Ltd's business quality as poor — 15/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, PG Foils Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on PG Foils Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of PG Foils Ltd's fair value is about ₹30 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →